Compliance officers in the pharmaceutical industry have a few new clues to consider from a top voice at the Securities and Exchange Commission about violations of the Foreign Corrupt Practices Act, and how to avoid them.
In remarks at a recent pharmaceutical industry conference, SEC Director of Enforcement Andrew Ceresney described FCPA enforcement in the pharma sector as a high priority. “Our FCPA focus obviously covers many industries,” Ceresney said. “But the pharma industry is one on which we have been particularly focused in recent years.”
FCPA risk is painfully high for pharma and medical device companies, because so much of their business overseas involves working with government-run healthcare systems. “Pharmaceutical representatives have regular contact with doctors, pharmacists, and... To get the full story, subscribe now.
Join the Community
Full, instant access
Single-user subscription, one year | $1,199.00
For multi-user subscriptions, call (888) 519-9200